glp-1 cv outcome trials Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes | Cardiovascular Diabetology GLP1 agonists: current and future

This data suggests that more healthcare providers are seeing the benefits of these medications for treating obesity, which is a significant public health shift, Yee Hui Yeo, MD, a clinical fellow in the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai and co-first author of the study said in a press release

If this describes you, adjusting your injection day so that this trough period falls on days when your eating environment is most controlled (like structured workdays rather than weekends) can help considerably

Not yet

Cambia is deploying it in real time North Dakota in February, Arkansas pending with Highmark and BCBS Michigan running their own versions